Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Unknown 2Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Breast 2Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Gynecologic 1Dermatologic 1Classical hematology 1

Conditions

Melanoma 1

Interventions

pembrolizumab 70Nivolumab 47Ipilimumab 27Specimen Handling 15Magnetic Resonance Spectroscopy 15trametinib 14Biopsy 13dabrafenib 11cemiplimab 11avelumab 11Cyclophosphamide 11binimetinib 10Radiotherapy 9CTLA-4 Antigen 9fludarabine 8encorafenib 7atezolizumab 7Radiosurgery 7Immunoglobulin G 7Disulfides 7Cisplatin 7fludarabine phosphate 6durvalumab 6tislelizumab 5relatlimab 5lenvatinib 5dostarlimab 5Pemetrexed 5Paclitaxel 5Introns 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Pharmacogenomic Testing × Dermatologic × Clear all
NCT02581930 2026-04-30

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
18 enrolled 10 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡